Evidence map›Paper›PMID 40170233›Full record

Trial reportJournal of the National Cancer Institute2025

A randomized study of 2 risk assessment models for individualized breast cancer risk estimation.

Adrià López-Fernández, Laura Duran-Lozano, Guillermo Villacampa, Mónica Pardo, Eduard Pérez, Esther Darder, Anna Vallmajó, Rosa Alfonso, Mara Cruellas, Ariadna Roqué and 24 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of the National Cancer Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Adrià López-FernándezVall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.ORCID 0000-0002-2844-5998
Laura Duran-LozanoVall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Guillermo VillacampaOncology Data Science (ODysSey) Group, VHIO, Barcelona, Spain.ORCID 0000-0003-4868-6585
Mónica PardoVall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Eduard PérezVall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.ORCID 0009-0000-5728-2844
Esther DarderHereditary Cancer Program, Catalan Institute of Oncology, Josep Trueta University Hospital, IDIBGI, Girona, Spain.ORCID 0000-0002-7764-1397
Anna VallmajóGenetic Counseling Unit, Arnau de Vilanova University Hospital, Lleida, Spain.ORCID 0009-0006-2816-5060
Rosa AlfonsoMedical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Mara CruellasVall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.ORCID 0000-0002-6953-9675
Ariadna RoquéHereditary Cancer Program, Catalan Institute of Oncology, Josep Trueta University Hospital, IDIBGI, Girona, Spain.ORCID 0000-0003-0492-7463
Mireia CartróHereditary Cancer Unit, Corporació Sanitaria Parc Taulí, Sabadell, Spain.ORCID 0009-0004-3055-4853
Adriana BareasVall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Estela CarrascoVall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.ORCID 0000-0003-1964-7675
Alejandra RezqallahVall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.ORCID 0000-0001-9758-9402
Ana Raquel Jimenez-MacedoMedical Oncology Service, Consorci Sanitari de Terrassa, Terrassa, Spain.ORCID 0009-0005-2796-8569
Sara Torres-EsquiusVall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.ORCID 0000-0001-7540-7284
Maite TorresMedical Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Consol LopezMedical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Martín EspinosaBreast Surgical Unit, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.ORCID 0000-0002-4293-3875
Alex TeuléHereditary Cancer Program, Catalan Institute of Oncology-ICO, ONCOBELL-IDIBELL, L'Hospitalet de Llobregat, Spain.ORCID 0000-0003-0028-7200
Elisabet MuntéHereditary Cancer Program, Catalan Institute of Oncology-ICO, ONCOBELL-IDIBELL, L'Hospitalet de Llobregat, Spain.ORCID 0000-0001-8396-8284
Noemi TusetGenetic Counseling Unit, Arnau de Vilanova University Hospital, Lleida, Spain.ORCID 0000-0001-8432-7059
Orland DiezArea of Clinical and Molecular Genetics, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Lidia FeliubadalóHereditary Cancer Program, Catalan Institute of Oncology-ICO, ONCOBELL-IDIBELL, L'Hospitalet de Llobregat, Spain.ORCID 0000-0002-1736-0112
Conxi LázaroHereditary Cancer Program, Catalan Institute of Oncology-ICO, ONCOBELL-IDIBELL, L'Hospitalet de Llobregat, Spain.ORCID 0000-0002-7198-5906
Gemma LlortHereditary Cancer Unit, Corporació Sanitaria Parc Taulí, Sabadell, Spain.
Tim CarverCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0003-1508-3091
Lorenzo FicorellaCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-0577-1571
Nasim MavaddatCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0003-0307-055X
Anna MercadéServei Veterinari de Genètica Molecular (SVGM), Universitat Autonòma de Barcelona, Cerdanyola del Vallès, Spain.ORCID 0000-0002-4714-3565
Antonis C AntoniouCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0001-9223-3116
Joan BrunetHereditary Cancer Program, Catalan Institute of Oncology, Josep Trueta University Hospital, IDIBGI, Girona, Spain.ORCID 0000-0003-1945-3512
Teresa Ramon Y CajalMedical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.ORCID 0000-0003-3490-3585
Judith BalmañaVall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.ORCID 0000-0002-0762-6415

Funding

Agencia Estatal de InvestigaciónBreast Cancer Research Foundation BCRF-23-203Cancer Research UK PPRPGM-Nov20\100002Cellex FoundationCenter of Excellence Severo Ochoa CEX2020-001024-S/AEI/10.13039/501100011033CIHR #155865European UnionGeneralitat de CatalunyaGenome Canada #13529Government of CanadaInstituto de Salud Carlos III PI19/00553Instituto de Salud Carlos III PI19/01195Instituto de Salud Carlos III PI23/00017Instituto de Salud Carlos III PI23/01047Secretariat for Universities and Research of the Department of Business and Knowledge 2021SGR01112State Agency for Research
6 · The paper itself

Abstract

backgroundEstimating breast cancer risk involves quantifying genetic and non-genetic factors. This supports health interventions and risk communication to ensure adherence to screening recommendations. This study evaluated the change in risk estimation when incorporating breast density and polygenic risk score (PRS) into the baseline cancer risk assessment and compared the efficacy of 2 risk-assessment delivery models.

methodsThis 2-step study included 663 healthy women with a family history of breast cancer in which no pathogenic variants were identified. First, breast density and PRS were added to the baseline risk assessment for all participants. A randomized intervention study compared 2 delivery models (in-person vs pre-recorded video) for risk assessment in women at moderate or average risk. All tests were 2-sided.

resultsBreast density and PRS reclassified the risk group into 33% of the participants, with only 5% reclassified as high-risk. After disclosure of their estimated multifactorial risk, 65% of women aligned their risk perception with their estimated risk, compared to 47% at baseline (P < .05). No statistically significant differences were found in the primary endpoint cancer worry, mean = 10.2 (SD = 3.1) vs 10.1 (2.7), between delivery models. In-person delivery had slightly better psychological outcomes (excluding the primary outcome) and higher satisfaction, though few participants in the video group sought in-person clarification.

conclusionsIncorporating breast density and PRS into risk assessments led to substantial reclassification, with 1 in 5 women facing de-escalated surveillance. Personalized assessments improve objective perceptions alignment. A model using a pre-recorded video-based model matches in-person delivery for moderate and average-risk women and is scalable for population-level implementation.

Indexed as

Breast NeoplasmsAdultAgedBreast DensityEarly Detection of CancerFemaleHumansMiddle AgedPrecision MedicineRisk AssessmentRisk Factors

Identifiers

PMID40170233
PMCPMC12342814

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.